news
Novartis and Ratio to progress next-gen radiotherapeutic
The collaboration between Novartis Pharma AG and Ratio Therapeutics aims to advance a potential best-in-class therapeutic candidate as a treatment for a difficult-to-treat cancer.
List view / Grid view
Novartis Pharma AG
news
Novartis collaboration to innovate subcutaneous drug delivery
The multi-target biologic-focused agreement could enhance treatment convenience by improving subcutaneous administration options for patients.
news
US ophthalmic drugs market set to pass $34bn by 2025
Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action...
article
Raman In-Depth Focus 2016
In this supplement: Raman imaging evaluating counterfeit Cialis® tablets; analysis of capsule-based dry powder inhalers; Raman spectroscopy to authenticate medicines; Raman roundtable; as well as expert views...
article
RMMs In-Depth Focus
In this RMMs In-Depth Focus: the role of statistical analysis in validating rapid microbiological methods; considerations when using RMMs for use in pharmaceutical microbiology; & RMMs roundtable...
article
NIR: In-Depth Focus 2016
In this NIR In-Depth Focus: Moving to fast chemical imaging techniques in process control; Progress in near-infrared techniques in biomedical research...
article
RMM: In-Depth Focus 2015
In this RMM In-Depth Focus: Implementation of a rapid methods portfolio at a pharmaceutical manufacturing site; Use of RMMs in quality control: challenges and benefits; Rapid assay for bioburden and other contaminations; RMM Roundtable...
article
RMM: In-Depth Focus 2014
Michael J. Miller discusses rapid microbiological methods and the regulatory environment, the Online Water Bioburden Analyzer Workgroup look at the path to implementing Online Water Bioburden Analyzers, plus RMM roundtable...
article
NIR: In-Depth Focus 2014
In this free-to-view NIR in-depth focus: Moving towards continuous manufacturing with NIRS and NIR-CI systems, Monitoring of pharmaceutical powder mixing by NIR spectroscopy...
news
Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome
28 March 2014 | By Novartis
Advisory Committee members voted against RLX030 for the treatment of acute heart failure (AHF)...
article
Ten years of siRNA – a clinical overview
10 July 2012 | By Katharina Bruno, Principal Scientist, Technical Research & Development (TRD), Novartis Pharma AG
In 2001, small interfering RNA (siRNA) was discovered as the mediator of RNA interference (RNAi), a transient and specific repression mechanism of protein expression1. After the pharmaceutical industry became aware of the intrinsic versatility and potential of this molecule, a race to develop the first siRNA based drug began. However,…
article
PAT supplement 2011
In this PAT supplement: The historical development of the FDA's PAT initiative and its present course; Implementation of modelling approaches in the QbD framework: Examples from the Novartis experience; Challenges in development and implementation of spectroscopic techniques as PAT Analysers...
article
Genomics / Sequencing supplement 2011
In this Genomics / Sequencing supplement: NGS powers up drug discovery and healthcare; Impact of novel sequencing technology on transcriptome analysis; Making sense of nonesense (and missense): Bringing the results of recent genetic studies into the drug discovery laboratory...
news
Novartis studies show Onbrez® Breezhaler® & tiotropium provided greater increase in lung function than tiotropium alone
10 February 2011 | By Novartis
Patients with COPD treated with Onbrez® Breezhaler® & tiotropium notice improvements...
article
Lab Automation Roundtable
12 December 2009 | By
Participants: Dr Gordon R Alton, President and CEO, Altonyx Consulting / Dr Scott Bowes Scientist, Novartis / Dr Sheraz Gul, Vice President and Head of Biology, European ScreeningPort / Chris Molloy, Vice President of Corporate Development, IDBS
